CLAIMS

1. A compound having the following Structure (II):



(II)

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, for use in treating neurophathic pain; wherein

R^{1a} is C_1-C_6 alkyl;

R^{1b} is C_1-C_6 alkyl,

R^2 is $–NHR^{3a}$, $–NHC(=O)R^{3b}$, $–NHC(=S)R^{3b}$, or $–C(=O)R^{3c}$;

R^{3a} is hydrogen, C_1-C_6 alkyl, or C_3-C_6 cycloalkyl, each of which is optionally substituted with one or more substituents selected from the group consisting of hydroxyl, C_3-C_6 cycloalkyl, $-NHS(O)_2CH_3$, heterocyclyl, $-C(=O)OH$, $-C(=O)N(R^{3d})R^{3d}$, or $-N(R^{3d})R^{3d}$;

R^{3b} is C_1-C_6 alkyl, C_3-C_6 cycloalkyl, or heterocyclyl each of which is optionally substituted with one or more substituents selected from the group consisting of hydroxyl, halo, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, $-NHS(O)_2CH_3$, $-N(R^{3d})R^{3d}$, heterocyclyl, $-C(=O)OH$, $-C(=O)N(R^{3d})R^{3d}$, $-NHC(=O)CH_3$, $-CH_2C(=O)OH$,

R^{3c} is $-N(R^{3d})R^{3d}$ or heterocyclyl;

R^{3d} is, at each occurrence, independently hydrogen, C_1-C_6 alkyl, or C_3-C_6 cycloalkyl;

L is –NH– or $–CH_2NH–$; and

X is N and Y is CH or X is CH and Y is N,

provided that:

when R^{1a} and R^{1b} are both $–CH_3$ then R^2 does not have the following structure:

–NH_2 or .

2. The compound of claim 1, wherein R^{1a} is selected from one of the following options:

a) R^{1a} is C_1-C_6 alkyl; or

b) R^{1a} is methyl.

3. The compound of claim 1 or claim 2, wherein R^{1b} is selected from one of the following options:

a) R^{1b} is C_1-C_6 alkyl; or

b) R^{1b} is methyl.

4. The compound of any one of claims 1-3, wherein the compound has the following structure:



,

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

5. The compound of any one of claims 1-4, wherein R^2 is selected from any one of the following options:

a) R^2 is –NHR^{3a};

b) R^2 has one of the following structures:

-NH_2;  ;  ;  ;  ;  or  ;

c) R^2 is –$NHC(=O)R^{3b}$;

d) R^2 has one of the following structures:

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;


;

;

;

;

or

; or

e) R^2 is –NHC(=S)R^{3b};

f) R^2 has the following structure:


;

g) R^2 is –C(=O)R^{3c};

h) R^2 has one of the following structures:


or

;

i) R^2 has one of the following structures:

-NH_2;

;

;

;

;

;

;

;

;



j) R^2 has one of the following structures:



6. The compound of any one of claims 1-5, wherein X and Y are selected from one of the following options:

a) X is CH and Y is N; or

b) X is N and Y is CH.

7. The compound of any one of claims 1-6, wherein L:

a) L is –NH–; or

b) L is –CH_2NH–.

8. The compound of any one of claims 1-7, wherein the compound has one of the following structures:


;


;


;

or


,

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

9. A pharmaceutical composition comprising the compound of any one of claims 1-8, and a pharmaceutically acceptable carrier, diluent or excipient, for use in treating neuropathic pain.

10. Use of a compound of any one of claims 1-8, or the pharmaceutical composition of claim 9 in the manufacture of a medicament for treating neuropathic pain.